The OPTIMISE‑AR paper was published in @thelancetoncol.bsky.social last week. This introduces a practical toolkit to support the analysis and visualisation of patient‑reported outcomes (PROs) in early‑phase dose‑finding oncology trials. 🧪

Delighted to share OPTIMISE-ROR – recommendations to help embed patient-reported outcomes (PROs) more meaningfully in dose-finding oncology trials. It sets out core PRO objectives to support tolerability assessment, dose selection, and PRO strategy for subsequent studies. tinyurl.com/45thervu.

International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR - PubMed

This foundational guidance outlines key PRO research objectives in DFOTs. By facilitating the systematic integration of PROs, this guidance supports the utilization of patient-centered evidence for the tolerability and efficacy assessment of therapies to inform dose escalation, optimization, and reg …

tinyurl.com

Congratulations to Cross-Sector Experience Award recipient @christinayap.bsky.social 🎉 Through this award Prof Yap will work with AstraZeneca & Bayer to improve the design of early-phase trials, ensuring they are more effective & impactful for patients. 👉 bit.ly/45a0VWy #CrossSector @icr.ac.uk

A real pleasure running this workshop with you and Devin Peipert - thank you so much! Had such an engaging and interactive group too!

Amylou Dueck, PhD@biostatgirl.bsky.social · last yr.

Presenting a #patientreportedoutcomes workshop at Society for Clinical Trials 46th Annual Meeting! #SCT2025 #clinicaltrials #PROs @christinayap.bsky.social

Thank you for the kind invitation to share insights on the value of PROs in phase I dose-finding trials. A fantastic conference in the beautiful city of Barcelona - I’ve learnt so much too! Such a privilege to be part of it!

EORTC Quality of Life Group (QLG)@qol.eortc.org · last yr.

🩺 Phase 1 oncology trials focus on safety—but PROs can add real value. They complement clinician-reported dose-limiting toxicity (DLTs), offering a fuller view of treatment impact. Interest is growing across patients, researchers & regulators. - @christinayap.bsky.social @eortc.org #QoLConf25

Passionate about cancer trials, patient-reported outcomes (PROs) & innovative methods? Join the Early Phase and Adaptive Trials Group at @icr-ctsu.bsky.social @icrlondon.bsky.social for an exciting undergraduate summer scholarship in early phase trials & PROs! Deadline: 26/01/25 shorturl.at/1h565